UK clinical AI technology company,announced on Thursday that it had extended its existing collaboration with multinational pharmaceutical firm, Bayer, for the development of new treatments using clinical AI.
Sensyne will partner with Bayer’s division, LifeHub UK, which makes up a wider network of global innovation hotspots with the aim of catalysing impactful solutions at the intersection of health and nutrition.
Specifically, the division, which launches today, is designed to streamline disease detection as well as data-driven drug discovery with the aid of AI-enabled imaging solutions.
Commenting on the extended collaboration, CEO of Sensyne Health, Lord Paul Drayson explained, "Initiatives like this are essential to quickly maximise the opportunity AI presents to improve patient care and accelerate medical research.”
Sensyne will be one of the first companies to establish a presence in the LifeHub, with the first project focusing on radiology solutions using the firm’s AI technology platform in order to identify digital solutions for automated image evaluation.
The project will analyse research from three million anonymised, ethically sourced NHS patient records and data provided through Sensyne’s partnerships with NHS trusts, with the NHS remaining the controller of all patient data.
Essentially, Sensyne will act as a ‘docking station’ for anonymised patient data analysis under strict oversight from the NHS trust, the company emphasised -- this will ensure ethical governance is practiced under NHS principles, EU data protection law and regulatory guidance.
Kemal Malik, a Bayer Board Member for Innovation, expressed his delight at the programme, stating that its launch reflected a firm belief in the transformative potential of AI in healthcare, he commented:
"LifeHub UK's roadmap is a perfect fit to Bayer's Open Innovation strategy, which is designed to leverage places, programmes and partnerships - such as strategic alliances and joint ventures - in the life sciences fields of pharmaceuticals and agriculture."
Additionally, the firm revealed its intentions to conduct further joint R&D activities with Bayer to further advance imaging solutions using AI.
Follow News & Updates from Sensyne Health here:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
Intelligent Ultrasound Group (MED) has announced that one of its BodyWorks Point-of-Care Ultrasound Simulator (“PoCUS”) has been deployed to the emergency simulation centre at the NHS Nightingale Hospital at London's ExCel centre.
"We appreciate the strong support of Senex and the South Australian Government while the Company adjusts to this dynamic new operating environment," said Joe Salomon, Managing Director of Oilex.
The emergency loans scheme for businesses struggling to survive amid the coronavirus pandemic has been revamped following strong criticism. The Treasury said it had received more than 130,000 loan enquires from firms but fewer than 1,000 had been approved.